Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
The purpose of this study is to collect and store tumor tissue, blood, and bone marrow
samples from patients with soft tissue sarcoma that will be tested in the laboratory.
Collecting and storing samples of tumor tissue, blood, and bone marrow from patients to test
in the laboratory may help the study of cancer.
I. Collect human tumor tissue and other biological specimens (blood, serum, and bone marrow)
from patients with rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma diagnosed
and/or treated at a Children's Oncology Group (COG) member institution.
II. Provide a repository for storage of tissue and other biological specimens collected by
COG investigators from these patients.
III. Make these specimens available for approved projects by laboratory-based investigators.
IV. Collect clinical data on these patients who are not being treated on a COG therapeutic
V. Define and compare the clinical features of patient subgroups with alveolar
rhabdomyosarcoma whose tumors carry the t(2;13), t(1;13) or neither translocation.
VI. Investigate the relationship between evidence of submicroscopic disease and response
rate (CR/PR), failure-free survival, and survival of patients with alveolar
rhabdomyosarcoma, as determined by positive or negative reverse transcriptase-polymerase
chain reaction (RT-PCR) assay for the t(2:13) and t(1:13) on peripheral blood and bone
marrow specimens obtained at diagnosis.
VII. Compare the clinical, cytogenetic, and molecular biologic features of patient subgroups
with anaplastic rhabdomyosarcoma and other subtypes of rhabdomyosarcoma.
Surgical tissue, bone marrow, and blood specimens are collected at diagnosis (initial or
relapse) and, if applicable, at the development of a second primary tumor. Specimens are
used for research purposes. A certificate of confidentiality protecting the identity of
research participants in this project has been issued by the National Cancer Institute.
Patients who are not enrolled on a Children's Oncology Group treatment trial are followed
every 6 months for at least 10 years or until disease progression or development of a second
- Histologically or cytologically confirmed diagnosis of 1 of the following:
- Non-rhabdomyosarcoma soft tissue sarcoma
- Desmoid fibromatosis
- Desmoplastic round cell tumors
- Undifferentiated embryonal sarcoma of the liver
- Unclassified soft tissue sarcoma that is too undifferentiated to be placed in a
specific pathologic category in the WHO classification (often called
"undifferentiated soft tissue sarcoma" or "soft tissue sarcoma NOS")
- Other soft tissue neoplasms, excluding benign tumors
- Must have pathological specimens of tumor-containing tissue or bone marrow (beyond
that needed by the institution for diagnosis) available for study
- No malignant rhabdoid tumor, Ewing sarcoma/primitive neuroectodermal tumor, or
osteogenic sarcoma of bone
- No osteogenic sarcoma